Premium
Neurochemical biomarkers in the differential diagnosis of movement disorders
Author(s) -
Mollenhauer Brit,
Trenkwalder Claudia
Publication year - 2009
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.22510
Subject(s) - neurochemical , corticobasal degeneration , progressive supranuclear palsy , dementia , dementia with lewy bodies , cerebrospinal fluid , differential diagnosis , lewy body , medicine , pathology , neuroscience , central nervous system , disease , movement disorders , degenerative disease , synucleinopathies , neurology , parkinson's disease , psychology , alpha synuclein
In recent years, the neurochemical analysis of neuronal proteins in cerebrospinal fluid (CSF) has become increasingly accepted for the diagnosis of neurodegenerative dementia diseases such as Alzheimer's disease and Creutzfeldt–Jakob disease. CSF surrounds the central nervous system, and in the composition of CSF proteins one finds brain‐specific proteins that are prioritized from blood‐derived proteins. Levels of specific CSF proteins could be very promising biomarkers for central nervous system diseases. We need the development of more easily accessible biomarkers, in the blood. In neurodegenerative diseases with and without dementia, studies on CSF and blood proteins have investigated the usefulness of biomarkers in differential diagnosis. The clinical diagnoses of Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration still rely mainly on clinical symptoms as defined by international classification criteria. In this article, we review CSF biomarkers in these movement disorders and discuss recent published reports on the neurochemical intra vitam diagnosis of neurodegenerative disorders (including recent CSF α‐synuclein findings). © 2009 Movement Disorder Society